参考文献/References:
[1] Czernin J,Allen-Auerbath M,Schelbert HR.Improvements in cancer staging with PET/CT:literature-based evidence as of September 2006.J Nucl Med,2007,48suppl 1:78s-88.
[2] Schöder H,Noy A,Gönen M,et al.Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma.J Clin Oncol,2005,23(21):4643-4651.
[3] Cerfolio RJ,Bryant AS,Winokur TS,et al.Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer.Ann Thorae Surg,2004,78(6):1903-1909.
[4] Radan L,Ben-Haim S,Bar-shalom R,et al.The role of FDG-PET/CT in suspected reculrrence of breast cancer.Cancer,2006,107(11):2545-2551.
[5] HÜbner KF,Buonocore E,Gould HR,et al.Differentiating benign from malignant lung lesions using "quantitative" paratneters of FDG PET images.Clin Nucl Med,1996,21(12):941-949.
[6] Dehdashti F,Mortimer JE,Sieqel BA,et al.Positron tomographic assessment of estrogen receptors in breast cancer.comparison with FDG-PET and in vitro receptor assays.J Nucl Med,1995,36(10):1766-1774.
[7] 俎栋林.核磁共振成像学.北京:高等教育出版社,2004:231-315.
[8] Fiebach JB,Schellinger PD,Sartor K,et al.脑卒中磁共振成像.孙波,译.北京:人民卫生出版社,2005:13-19.
[9] Antoch G,Stattaus J,Nemat AT,et al.Non-small cell lung cancer:dual-modality PET/CT in preoperative staging.Radiology,2003,229(2):526-533.
[10] Brush J,Boyd K,Chappell F,et al.The value of FDG positron emis-sion tomography/computerised tomography (PET/CT) in pre-oper-ative staging of colorectal cancer:a systematic review and economic evaluation.Health Technol Assess,2011,15(35):1-192,iii-iv.
[1l] Pelosi E,Preqno P,Penna D,et al.Role of whole-body[18F] fluo-rodeoxyglucose positron emission tomography/computed tomogra-phy (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin Lymphoma. Radial Med,2008,113(4):578-590.
[12] Freudenberg LS,Antoch G,SchÜtt P,et al.FDG-PET/CT in restaging of patients with lymphoma.Eur J Nucl Med Mol Imaging,2004,31(3):325-329.
[13] Ohba Y,Nomori H,Mori T,et al.Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F18 in imaging non-small cell lung cancer?.J Thorac Cardiovasc Surg.2009.138(2):439-445.
[14] Mori T,Nomori H,Ikeda K,et al.Diffusion-weighted magnetic reso-nance imaging for diagnosing malignant pulmonary nodules/masses:comparison with positron emission tomography.J Thorac Oncol,2008,3(4):358-364.
[15] Chen W,Jian W,Li HT,et al.Whole-body diffusion-weighted imaging vs.FDG-PET for the detection of non-small-cell lung can-cer.How do they measure up?.Magn Reson Imaging,2010,28(5):613-620.
[16] Ohno Y,Koyama H,Onishi Y,et al.Non-small cell lung cancer:whole-body MR examination for M-stage assessment-utility for whole-body diffusion weighted imaging compared with integrated FDG PET/CT.Radiology,2008,248(2):643-654.
[17] Takenaka D,Ohno Y,Matsumoto K,et al.Detection of bone metas-tases in non-small cell lung cancer patients:comparison of whole-body diffusion-weighted imaging (DWI) whole-body MR imaglng without and with DWI,whole-body FDG-PET/CT and bone seintig-raphy.J Magn Reson Imaging,2009,30(2):298-308.
[18] Heusner TA,Kuemmel S,Koeninger A,et al.Diagnostic value of diffusion-weighted magnetic resonance imaging(DWI)compared to FDG PET/CT for whole-body breast cancer staging.Eur J Nucl Med Mol Imaging,2010,37(6):1077-1086.
[19] Ono K,Ochiai R,Yoshida T,et al.Comparison of diffusion-weighted MRI and 2-[fluorine-18] -fuoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases.J Magn Reson Imaging,2009,29(2):336-340.
[20] Pinilla I,Gómez-León N,Del Campo-Del Val L,et al.Diagnostic value of CT.PET and combined PET/CT performed with low-dose unenhaneed CT and full-dose enhanced CT in the initial staging of lymphoma.Q J Nucl Med Mol Imaging,2011,55(5):567-575.
[21] Li S,Xue HD,Li J,et al.Application of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lym-phoma.Chin Med Sci J,2008,23(3):138-144.
[22] Farsad M,Schiavina R,Castellueei P,et al.Detection and localiza-tion of prostate cancer:correlation of 11C-choline PET/CT with histopathologic step-section analysis.J Nucl Med,2005,46(10):1642-1649.
[23] Kim CK,Park BK,Han JJ,et al.Diffusion-weighted imaging of the prostate at 3T for differentiation of malignant and benign tissue in transition and peripheral zones:preliminary results.J Comput Assist Tomogr,2007,31(3):449-454.
[24] De Geus-Oei LF,Pieters GF,Bonenkamp JJ,et al.18F-FDG PET reduces unnecessary hemithyroideetomies for thyroid nodules with inconclusive cytologic results.J Nucl Med,2006,47(5):770-775.
[25] Ren S,Liu CH,Bai RJ.Value of diffusion weighted imaging in diagnosis of nodular lesions of thyroid:a preliminary study.Zhonghua Yi Xue Za zhi,2010,90(47):3351-3354.
[26] Traugott AL,Dehdashti F,Trinkaus K,et al.Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglueose positron emission tomogm-phy:Interim analysis.World J Surg,2010,34(6):1247-1253.
[27] Razek AA,Sadek AG,Kombar OR,et al.Role of apparent diffusion coefficient values in differentiation between malignant and benign solitary thyroid Nodules.AJNR Am J Neuroradiol,2008,29(3):563-568.
[28] Park JW,Kim JH,Kim SK,et al.A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatoeellular carcinoma.J Nucl Med,2008,49(12):1912-1921.
[29] Yu JS,Chung JJ,Kim JH,et al.Detection of small intrahepatie metastases of hepatoeellular carcinomas using diffusion-weighted imaging:comparison with conventional dynamic MRI.Magn Reson Imaging,2011,29(7):985-992.
[30] Nomori H,Mori T,Ikeda K et al.Diffusion-weighted magnetic reso-nance imaging can be used in place of positron emission tomogra-phy for N staging of non-small cell lung cancer with fewer false-pos-itive results.J Thorae Cardiovase Surg,2008,135(4):816-822.
[31] Usuda K,Zhao XT,Sagawa M,et al.Diffusion-weighted imaging is superior to positron emission tomography in the detection and nodal assessment of lung cancers.Ann Thorac Surg,2011,91(6):1689-1695.
[32] Schmidt GP,Baur-Melnyk A,Hang A,et al.Comprehensive imag-ing of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.Eur J Radiol,2008,65(1):47-58.
[33] Nagamachi S,Wakamatsu H,Kiyohara S,et al.Comparison of diag-nostic and prognostic capabilities of 18F-FDG-PET/CT.1,131I-scintig-raphy,and diffusion-weighted magnetic resonance imaging for post-operative thyroid cancer.Jpn J Radiol,2011,29(6):413-422.
[34] Beer AJ,Eiber M,Souvatzoglou M,et al.Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in 11C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer.Mol Imaging Biol,2011,13(2):352-361.
[35] Ho KC,Lin G,Wang JJ,et al.Correlation of apparent diffusion coefficients measured by 3 T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer.Eur J Nucl Med Mol Imaging,2009,36(2):200-208.
[36] Gu J,Khong PL,Wang S,et al.Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer:correlation with FDG-PET/CT.Mol Imaging Biol,2011,13(5):1020-1028.
[37] Nakajo M,Kajiya Y,Kaneko T,et al.FDG PET/CT and diffusion-weighted imaging for breast cancer:prognostic value of maximum standardized uptake values and apparent diffusion coefficient val-ues of the primary lesion.Eur J Nucl Med Mol Imaging,2010,37(11):2011-2020.
[38] Tanimoto K,Yoshikawa K,Obata T,et al.Role of glucose metabolism and cellularity for tumor malignancy evaluation using FDG-PET/CT and MRI.Nucl Med Commun,2010,31(6):604-609.
[39] Choi SH,Paeng JC,Sohn CH,Correlation of 18F-FDG uptake with appamnt diffusion coefficient ratio measured on standard and high b value diffusion MRI in head and neck cancer.J Nucl Med,2011,52(7):1056-1062.
[40] Fruehwald-Pallamar J,Czerny C,Mayerhoefer ME,et al.Functional imaging in head and neck squamous cell carcinoma:correlation of PET/CT and diffusion-weighted imaging at 3 Tesla.Eur J NCucl Med Mol Imaging,2011,38(6):1009-1019.
[4l] Wu X,Korkola P,Pertovaara H,et al.No correlation between glu-cose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma:a PET/CT and DW-MRI study.Eur J Radiol,2011,79(2):117-121.
[42] Punwani S,Prakash V,Bainbridge A,et al.Quantitative diffusion weighted MRI:a functional biomarker of nodal disease in Hodgkin lymphoma?.Cancer Biomark,2010,7(4):249-259.
[43] LaMon SM,Schwartz LH.18F-FDG PET as a candidate for "quali-fled biomarker":functional assessment of treatment response in oncology.J Nucl Med,2006,47(6):901-903.
[44] Hickeson M,Yun M,Matthies A,et al.Use of a corrected standardized uptake value based on the lesion size Oil CT permits accurate characterization of lung nodules on FDG PET.Eur J Nucl Med Mol Imaging,2002,29(12):1639-1647.
[45] Bilgili Y,Unal B.Effect of region of interest on interobserver vari-ance in apparent diffusion coefficient measures.AJNR Am J Neu-mradiol,2004,25(1):108-111.
[46] 赵周社,辛军,郭启勇,等.多种正电子示踪剂PET联合显像在肿瘤基础研究、临床诊断和疗效监测中应用进展.中国临床医学影像杂志,2009,20(10):764-769.
[47] 郭洪波,于金明,杨国仁.1叩.FDG PET肿瘤显像中应注意的几个问题.中华核医学杂志,2007,27(5):316-318.
[48] Cook GJ,Wegner EA,Fogelman I.Pitfalls and artifacts in 18F-FDG PET and PET/CT oncologic imaging.Semin Nucl Med,2004,34(2):122-133.
[49] 陈香,赵军,赵晋华.PET-MRI:值得期待的分子影像未来.国际放射医学核医学杂志,2008,32(4):196-201.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[4]孙昱,符达,刘兴党.卵巢癌循环肿瘤细胞的生物学特性及其临床应用进展[J].国际放射医学核医学杂志,2016,40(1):60.[doi:10.3760/cma.j.issn.1673-4114.2016.01.012]
Sun Yu,Fu Da,Liu Xingdang.Progress in biological characteristics and clinical application of circulating tumor cells in ovarian cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):60.[doi:10.3760/cma.j.issn.1673-4114.2016.01.012]
[5]蒿崑,孙珊珊,赵斌.规范化应用影像学检查对乳腺疾病诊断价值的研究进展[J].国际放射医学核医学杂志,2016,40(1):70.[doi:10.3760/cma.j.issn.1673-4114.2016.01.014]
Hao Kun,Sun Shanshan,Zhao Bin.The value of the standard application of medical imaging examination in the diagnosis of breast disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):70.[doi:10.3760/cma.j.issn.1673-4114.2016.01.014]
[6]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[7]唐令胜,刘朝晖,李红梅,等.低场磁共振DWI技术与常规MRI扫描对超急性脑梗死的诊断灵敏度的比较[J].国际放射医学核医学杂志,2016,40(3):187.[doi:10.3760/cma.j.issn.1673-4114.2016.03.006]
Tang Lingsheng,Liu Zhaohui,Li Hongmei,et al.Comparison of the diagnostic sensitivity of low-field magnetic resonance diffusion weighted imaging technology and conventional MRI scanning for super acute cerebral infarction[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):187.[doi:10.3760/cma.j.issn.1673-4114.2016.03.006]
[8]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[9]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[10]刘惠惠,李险峰.放射性心脏损伤诊断和防治的临床研究进展[J].国际放射医学核医学杂志,2016,40(5):374.[doi:10.3760/cma.j.issn.1673-4114.2016.05.008]
Liu Huihui,Li Xianfeng.Clinical research progress in diagnosis,prevention and treatment of radiation-induced heart disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):374.[doi:10.3760/cma.j.issn.1673-4114.2016.05.008]